Bigelow Investment Advisors’s AbbVie ABBV Stock Holding History

Bigelow Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,648	Closed	-$255K	–	154
2023 Q4	$255K	Buy	+1,648	New	+$240K	0.14%	135
2023 Q1	–	Sell	-1,456	Closed	-$235K	–	148
2022 Q4	$235K	Sell	1,456 -300	-17%	-$46K	0.14%	131
2022 Q3	$236K	Hold	1,756	–	–	0.14%	127
2022 Q2	$269K	Sell	1,756 -10	-0.6%	-$1.53K	0.15%	126
2022 Q1	$286K	Buy	1,766 +11	+0.6%	+$1.6K	0.13%	128
2021 Q4	$238K	Buy	+1,755	New	+$207K	0.11%	135
2021 Q3	–	Sell	-2,055	Closed	-$231K	–	140
2021 Q2	$231K	Buy	2,055 +50	+2%	+$5.63K	0.11%	133
2021 Q1	$217K	Hold	2,005	–	–	0.11%	135
2020 Q4	$215K	Buy	+2,005	New	+$193K	0.11%	135
2020 Q3	–	Sell	-2,075	Closed	-$204K	–	138
2020 Q2	$204K	Buy	+2,075	New	+$183K	0.13%	134
2020 Q1	–	Sell	-2,485	Closed	-$220K	–	134
2019 Q4	$220K	Buy	+2,485	New	+$206K	0.13%	151

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bigelow Investment Advisors's ABBV Position: Q1 2024 in Review

Bigelow Investment Advisors sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 1,648 shares — an estimated $255K sold.

Bigelow Investment Advisors first reported a position in ABBV in Q4 2019 and held it in 11 quarters. The position peaked at $286K in Q1 2022. 3,380 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Bigelow Investment Advisors reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
Bigelow Investment Advisors sold 1,648 AbbVie shares in Q1 2024, an estimated $255K.
Bigelow Investment Advisors first reported a position in AbbVie in Q4 2019 and held it in 11 quarters.
Bigelow Investment Advisors's AbbVie position peaked at $286K in Q1 2022.
3,380 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Bigelow Investment Advisors's 13F filing for Q1 2024, filed 8 May 2024.